A Phase 3 interventional study of Tolvaptan in Hyponatremia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-21.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing tolvaptan in Hyponatremia — none open to participants now, none under way, none of them phase 3. Tolvaptan · Hyponatremia.
Among the 20 studies testing tolvaptan in Hyponatremia, this one is the 6th largest by enrollment, is the only one that started in 2004, is one of 9 in phase 3, and was the 17th registered.
164 studies on the registry are indexed under Hyponatremia; 16 are open to participants now.
Browse Hyponatremia studies →None of the 20 studies testing tolvaptan in Hyponatremia is open now. The open studies under Hyponatremia, anywhere →
Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 14 Hyponatremia studies recruiting now, 13 (93%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 10 · Phase 4 7
First in 2003; this study’s year is marked. 1 started in 2004.
This study's enrollment of 111 is above the median of 60 across 97 interventional studies indexed under Hyponatremia.
Median enrollment 55 across the 20 interventional studies. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
17 studies in Hyponatremia by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 17 studies in Hyponatremia by Otsuka Holdings Co., Ltd., this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2004, is one of 8 in phase 3, and was the 13th registered.
Otsuka Holdings Co., Ltd.’s Hyponatremia studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing tolvaptan in Hyponatremia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 17 in Hyponatremia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the safety of long-term tolvaptan use in patients previously enrolled in shorter-term Phase 3 studies and gather information on the natural history of hyponatremia in the context of tolvaptan therapy and underlying disease states.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enrolled subjects began treatment with 15 mg tolvaptan QD. A titration between target doses of 15 mg, 30 mg, or 60 mg of trial medication was based on the subject's change in serum sodium concentration and clinical tolerance of the trial medication.
Drug: Tolvaptan
Once Daily
Participants With Adverse Events (AEs)
A TEAE was an AE that began after the first injection or was continuous from Baseline and was defined as any new medical problem, or exacerbation of an existing problem, whether or not it was considered drug-related by the study physician. An AE was considered serious if it was fatal; life-threatening; persistently or significantly disabling or incapacitating; required in-subject hospitalization or prolonged hospitalization; a congenital anomaly/birth defect; or other medically significant event that, based upon appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention to prevent the outcomes mentioned above.
Time frame: Baseline to Post-Week 214 follow-up visit
Participants With Laboratory Values Abnormalities Reported as TEAEs
The laboratory values were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria. Any value outside the normal range was flagged for the attention of the study physician who was to indicate whether the value was clinically significant for identifying laboratory values of potential clinical relevance. Participants noted with abnormal laboratory values are reported below.
Time frame: Baseline to Post-Week 214 follow-up visit
Participants With Electrocardiogram (ECG) Related Abnormalities Reported as TEAEs
The ECG was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance included abnormal values in HR outliers, PR outliers, QRS outliers, QT, QTcB, QTcF that were identified based on pre-defined criteria. Some of the pre-defined criteria for identifying ECG measurements of potential clinical relevance included: For QTcB and QTcF: baseline mean of QTcB and QTcF interval was new onset \>500 msec, 30 - 60 msec, \>60 msec; For QT: new onset \>500 msec; For QRS outliers: \>=25% change from baseline when QRS \>100 msec; PR outliers: \>=25% change from baseline when PR\>200 msec; HR outliers: 25% decrease from baseline and HR \<50 bpm or 25% increase from baseline and HR \>100 bpm. New onset (\>500 msec) in QT, QTcB, or QTcF means a participant who attained a value \>500 msec during treatment period but not at each baseline visit. The ECG-related abnormalities are reported as TEAEs are mentioned below.
Time frame: Baseline to Post-Week 214 follow-up visit
Participants With Vital Signs Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)
The vital signs were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure, respiratory rate and weight that were identified based on pre-defined criteria. Criteria for identifying vital signs of potential clinical relevance included: Heart rate, supine: \>= 120 beats per minute (bpm) + increase of ≥15 bpm from Baseline and \<=50 bpm + decrease of \>= 15 bpm; Diastolic Blood Pressure, Supine: \>=105 mmHg + increase of \>=15 mmHg and \<=50 mmHg + decrease of \>=15 mmHg; Systolic Blood Pressure, Supine: \>=180 mmHg + increase of \>=20 mmHg and \<= 90 mmHg + decrease of \>=20 mmHg; Temperature (degree C): Increase of \>=1.1 to \>=38.3C. The vital sign abnormalities were reported as TEAEs are mentioned below.
Time frame: Baseline to Post-Week 214 follow-up visit
Participants With Body Weight Abnormalities Reported as TEAEs
The body weight evaluation was one of the primary parameters to measure the safety and tolerability of individual participants. Every effort was made to ensure that body weight measurements were performed in a reproducible and consistent manner. The pre-defined criteria was change of ≥7% in body weight for both male and female. Participants were to wear the same type of clothes at each measurement, preferably a gown and no shoes. All body weight measurements were to have been taken post-void.
Time frame: Baseline to Post-Week 214 follow-up visit
Mean Change From Baseline in Serum Sodium Measurements
Sodium measurements obtained at designated intervals were compared to each participant's Baseline sodium level at the beginning of placebo-controlled therapy in their original trial and from Baseline on initiation of therapy in the open-label trial.
Time frame: Baseline of parent trial to Week 214
Change From Baseline in Percentage of Participants With Severe Hyponatremia
Percentage of participants with varying degrees of hyponatremia ("severe" \<130, "mild" 130-135, "normal" \>135 mEq/L) at Baseline and each study visit.
Time frame: Baseline to Week 214
Change From Baseline in Percentage of Participants With Mild Hyponatremia
Percentage of participants with varying degrees of hyponatremia ("severe" \<130, "mild" 130-135, "normal" \>135 mEq/L) at Baseline and each study visit.
Time frame: Baseline to Week 214
Change From Baseline in Percentage of Participants With Normal Sodium Levels
Percentage of participants with varying degrees of hyponatremia ("severe" \<130, "mild" 130-135, "normal" \>135 mEq/L) at Baseline and each study visit.
Time frame: Baseline to Week 214
Percentage of Participants Requiring Prescription of Fluid Restriction
Percentage of participants requiring prescription of fluid restriction for the express purpose of treating hyponatremia during each period of the trial. Assessed descriptively at each visit.
Time frame: Baseline to Post-Week 214 follow-up visit
Number of Participants Requiring Prescription of Hypertonic Saline
Percentage of participants requiring prescription of hypertonic saline for the express purpose of treating hyponatremia during each period of the trial, assessed descriptively at each visit.
Time frame: Baseline to Post-Week 214 follow-up visit
Percentage of Participants Requiring Prescription of Other Medicines
Percentage of participants requiring prescription of other medicines for the express purpose of treating hyponatremia during each period of the trial, assessed descriptively at each visit.
Time frame: Baseline to Post-Week 214 follow-up visit
Mean Change From Baseline in Body Weight by Visit for Those Participants Who Had Clinical Evidence of Hypervolemia at Baseline
Body weight at each visit (assessed only for those with clinical evidence of hypervolemia at Baseline) and was summarized using descriptive statistics.
Time frame: Baseline to Week 214
Mean Change From Baseline in SF-12 (Health Survey) Physical Component Summary (PCS)
The PCS assess the physical and mental dimensions of health-related quality of life. The PCS is equal to the sum of the items of endurance activities, strength activities, gross coordination activities, and fine coordination activities. The PCS is a computed score with weighted function based on the 12 questions from the 8 subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health) of the SF-12v1 questionnaire per instructions by the scale's publisher. The scale ranges from 0 to 100 with 0 representing the lowest level of health and 100 indicating the highest level of health.
Time frame: Baseline to Week 214
Mean Change From Baseline in SF-12 (Health Survey) Mental Component Summary (MCS)
The MCS assess the physical and mental dimensions of health-related quality of life. The MCS is equal to the sum of the items of concentration activities, calculating activities, language activities, and memory activities. The MCS is a computed score with weighted function based on the 12 questions from the 8 subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health) of the SF-12v1 questionnaire per instructions by the scale's publisher. The scale ranges from 0 to 100 with 0 representing the lowest level of health and 100 indicating the highest level of health.
Time frame: Baseline to Week 214
Change From Baseline in the Hyponatremia Disease-specific Survey
Analysis of individual items of Hyponatremia Disease-specific Survey was not conducted, because the analysis of Hyponatremia Disease-specific Survey was focused on the PCS and MCS summary scores since these 2 scores were developed. Subgroup analyses of Hyponatremia Disease-specific Survey were also not conducted.
Time frame: Baseline to Week 214
The trial was conducted in 111 enrolled participants at 33 trial centers. This is an extension study of trials NCT00072683 and NCT00201994. Approximately 50% participants may have been on tolvaptan previously, there was a minimum 7-day period off treatment between trials.
| Milestone | Tolvaptan |
|---|---|
| Started | 111 |
| Completed | 47 |
| Not completed | 64 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Withdrawal by subject | 13 |
| Withdrew: Adverse event | 30 |
| Withdrew: Met withdrawal criteria | 7 |
| Withdrew: Physician decision | 9 |
| Withdrew: Sponsor discontinued trial | 3 |
A TEAE was an AE that began after the first injection or was continuous from Baseline and was defined as any new medical problem, or exacerbation of an existing problem, whether or not it was considered drug-related by the study physician. An AE was considered serious if it was fatal; life-threatening; persistently or significantly disabling or incapacitating; required in-subject hospitalization or prolonged hospitalization; a congenital anomaly/birth defect; or other medically significant event that, based upon appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention to prevent the outcomes mentioned above.
| participants | Tolvaptan |
|---|---|
| Participants with TEAEs | 105 |
| Participants with serious TEAEs | 76 |
| Participants with severe TEAEs | 73 |
| Participants discontinued IMP due to TEAE | 19 |
| Participants discontinued IMP due to TEAE/death | 28 |
| Deaths | 19 |
The laboratory values were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria. Any value outside the normal range was flagged for the attention of the study physician who was to indicate whether the value was clinically significant for identifying laboratory values of potential clinical relevance. Participants noted with abnormal laboratory values are reported below.
| participants | Tolvaptan |
|---|---|
| Serum Chemistry-Blood creatinine increased | 4 |
| Serum Chemistry-Blood potassium increased | 4 |
| Serum Chemistry-Blood glucose increased | 3 |
| Serum Chemistry-Blood potassium decreased | 3 |
| SerumChemistry-Aspartate aminotransferaseincreased | 2 |
| Serum Chemistry-Blood cholesterol increased | 3 |
| Serum Chemistry-Blood sodium increased | 2 |
| Serum Chemistry-Hepatic enzyme increased | 2 |
| Serum Chemistry-Oxygen saturation decreased | 2 |
| Serum Chemistry-Hyperglycaemia | 5 |
| Serum Chemistry-Hyperkalaemia | 7 |
| Serum Chemistry-Hyperlipidaemia | 4 |
| Serum Chemistry-Hypernatraemia | 4 |
| Serum Chemistry-Hyperuricaemia | 3 |
| Serum Chemistry-Hypoglycaemia | 5 |
| Serum Chemistry-Hypokalaemia | 14 |
| Serum Chemistry-Hypomagnesaemia | 3 |
| Serum Chemistry-Hypoatraemia | 25 |
| Hematology-Anemia | 20 |
| Hematology-Thrombocytopenia | 2 |
| Hematology-International normalized ratioincreased | 4 |
| Hematology-White blood cell count increased | 2 |
The ECG was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance included abnormal values in HR outliers, PR outliers, QRS outliers, QT, QTcB, QTcF that were identified based on pre-defined criteria. Some of the pre-defined criteria for identifying ECG measurements of potential clinical relevance included: For QTcB and QTcF: baseline mean of QTcB and QTcF interval was new onset \>500 msec, 30 - 60 msec, \>60 msec; For QT: new onset \>500 msec; For QRS outliers: \>=25% change from baseline when QRS \>100 msec; PR outliers: \>=25% change from baseline when PR\>200 msec; HR outliers: 25% decrease from baseline and HR \<50 bpm or 25% increase from baseline and HR \>100 bpm. New onset (\>500 msec) in QT, QTcB, or QTcF means a participant who attained a value \>500 msec during treatment period but not at each baseline visit. The ECG-related abnormalities are reported as TEAEs are mentioned below.
| participants | Tolvaptan |
|---|---|
| Atrial fibrillation | 6 |
| Tachycardia | 4 |
| Atrial tachycardia | 3 |
| First degree atrioventricular block | 2 |
| Bradycardia | 2 |
| Sinus tachycardia | 2 |
| Ventricular tachycardia | 2 |
| Left bundle branch block | 1 |
| Tachyarrhythmia | 1 |
| Ventricular arrhythmia | 1 |
| Atrial flutter | 1 |
| ECG ST segment depression | 1 |
| Arrhythmia | 1 |
The vital signs were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure, respiratory rate and weight that were identified based on pre-defined criteria. Criteria for identifying vital signs of potential clinical relevance included: Heart rate, supine: \>= 120 beats per minute (bpm) + increase of ≥15 bpm from Baseline and \<=50 bpm + decrease of \>= 15 bpm; Diastolic Blood Pressure, Supine: \>=105 mmHg + increase of \>=15 mmHg and \<=50 mmHg + decrease of \>=15 mmHg; Systolic Blood Pressure, Supine: \>=180 mmHg + increase of \>=20 mmHg and \<= 90 mmHg + decrease of \>=20 mmHg; Temperature (degree C): Increase of \>=1.1 to \>=38.3C. The vital sign abnormalities were reported as TEAEs are mentioned below.
| participants | Tolvaptan |
|---|---|
| Hypotension | 13 |
| Hypertension | 8 |
| Pyrexia | 6 |
| Increased body temperature | 3 |
| Palpitations | 2 |
| Increased central venous pressure | 2 |
| Increased venous pressure | 1 |
| Orthostatic hypotension | 1 |
| Hypertensive crisis | 1 |
| Decreased orthostatic blood pressure | 1 |
| Increased weight | 5 |
| Decreased weight | 1 |
The body weight evaluation was one of the primary parameters to measure the safety and tolerability of individual participants. Every effort was made to ensure that body weight measurements were performed in a reproducible and consistent manner. The pre-defined criteria was change of ≥7% in body weight for both male and female. Participants were to wear the same type of clothes at each measurement, preferably a gown and no shoes. All body weight measurements were to have been taken post-void.
| participants | Tolvaptan |
|---|---|
| Increased weight | 5 |
| Decreased weight | 1 |
Sodium measurements obtained at designated intervals were compared to each participant's Baseline sodium level at the beginning of placebo-controlled therapy in their original trial and from Baseline on initiation of therapy in the open-label trial.
| mEq/L | Tolvaptan |
|---|---|
| Day 1 post-dose (N= 99) | 2.2 ± 3.3 |
| Day 14 (N= 110) | 5.2 ± 5.5 |
| Day 31 (N= 110) | 5.0 ± 4.8 |
| Week 10 (N= 110) | 5.0 ± 5.1 |
| Week 18 (N= 110) | 4.6 ± 5.4 |
| Week 26 (N= 110) | 4.2 ± 5.7 |
| Week 34 (N= 110) | 4.7 ± 5.9 |
| Week 42 (N= 110) | 5.2 ± 5.6 |
| Week 50 (N= 110) | 5.0 ± 5.9 |
| Week 58 (N= 110) | 5.0 ± 5.9 |
| Week 70 (N= 110) | 4.8 ± 5.8 |
| Week 82 (N= 110) | 4.8 ± 5.7 |
| Week 94 (N= 110) | 5.1 ± 5.8 |
| Week 106 (N= 110) | 5.0 ± 6.0 |
| Week 118 (N= 110) | 4.8 ± 5.9 |
| Week 130 (N= 110) | 4.9 ± 6.0 |
| Week 142 (N= 110) | 5.2 ± 5.9 |
| Week 154 (N= 110) | 5.2 ± 5.9 |
| Week 166 (N= 110) | 4.9 ± 5.8 |
| Week 178 (N= 110) | 4.8 ± 5.9 |
| Week 190 (N= 110) | 5.1 ± 6.1 |
| Week 202 (N= 110) | 5.0 ± 5.9 |
| Week 214 (N= 110) | 5.0 ± 5.9 |
Percentage of participants with varying degrees of hyponatremia ("severe" \<130, "mild" 130-135, "normal" \>135 mEq/L) at Baseline and each study visit.
| percentage of participants | Tolvaptan |
|---|---|
| Day 1 post-dose (N=99) | 20.2 ± 3.0 |
| Day 31 (N=110) | 9.1 ± 5.1 |
| Week 10 (N=110) | 11.8 ± 5.0 |
| Week 18 (N=110) | 13.6 ± 4.0 |
| Week 26 (N=110) | 16.4 ± 4.6 |
| Week 34 (N=110) | 14.5 ± 5.6 |
| Week 42 (N=110) | 12.7 ± 4.1 |
| Week 50 (N=110) | 10.9 ± 4.5 |
| Week 58 (N=110) | 13.6 ± 5.1 |
| Week 70 (N=110) | 12.7 ± 4.6 |
| Week 82 (N=110) | 10.9 ± 4.1 |
| Week 94 (N=110) | 10.9 ± 4.8 |
| Week 106 (N=110) | 12.7 ± 4.7 |
| Week 118 (N=110) | 12.7 ± 4.4 |
| Week 130 (N=110) | 11.8 ± 4.7 |
| Week 142 (N=110) | 11.8 ± 4.5 |
| Week 154 (N=110) | 11.8 ± 4.4 |
| Week 166 (N=110) | 11.8 ± 4.5 |
| Week 178 (N=110) | 11.8 ± 4.5 |
| Week 190 (N=110) | 11.8 ± 4.7 |
| Week 202 (N=110) | 11.8 ± 4.6 |
| Week 214 (N=110) | 11.8 ± 4.6 |
Percentage of participants with varying degrees of hyponatremia ("severe" \<130, "mild" 130-135, "normal" \>135 mEq/L) at Baseline and each study visit.
| percentage of participants | Tolvaptan |
|---|---|
| Day 1 post-dose (N=99) | 53.5 |
| Day 31 (N=110) | 33.6 |
| Week 10 (N=110) | 28.2 |
| Week 18 (N=110) | 33.6 |
| Week 26 (N=110) | 30.9 |
| Week 34 (N=110) | 26.4 |
| Week 42 (N=110) | 26.4 |
| Week 50 (N=110) | 31.8 |
| Week 58 (N=110) | 26.4 |
| Week 70 (N=110) | 30.9 |
| Week 82 (N=110) | 31.8 |
| Week 94 (N=110) | 28.2 |
| Week 106 (N=110) | 27.3 |
| Week 118 (N=110) | 28.2 |
| Week 130 (N=110) | 29.1 |
| Week 142 (N=110) | 25.5 |
| Week 154 (N=110) | 25.5 |
| Week 166 (N=110) | 30.9 |
| Week 178 (N=110) | 30.9 |
| Week 190 (N=110) | 30.9 |
| Week 202 (N=110) | 30.9 |
| Week 214 (N=110) | 30.9 |
Percentage of participants with varying degrees of hyponatremia ("severe" \<130, "mild" 130-135, "normal" \>135 mEq/L) at Baseline and each study visit.
| percentage of participants | Tolvaptan |
|---|---|
| Day 1 post-dose (N=99) | 26.3 |
| Day 31 (N=110) | 57.3 |
| Week 10 (N=110) | 60.0 |
| Week 18 (N=110) | 52.7 |
| Week 26 (N=110) | 52.7 |
| Week 34 (N=110) | 59.1 |
| Week 42 (N=110) | 60.9 |
| Week 50 (N=110) | 57.3 |
| Week 58 (N=110) | 60.0 |
| Week 70 (N=110) | 56.4 |
| Week 82 (N=110) | 57.3 |
| Week 94 (N=110) | 60.9 |
| Week 106 (N=110) | 60.0 |
| Week 118 (N=110) | 59.1 |
| Week 130 (N=110) | 59.1 |
| Week 142 (N=110) | 62.7 |
| Week 154 (N=110) | 62.7 |
| Week 166 (N=110) | 57.3 |
| Week 178 (N=110) | 57.3 |
| Week 190 (N=110) | 57.3 |
| Week 202 (N=110) | 58.2 |
| Week 214 (N=110) | 57.3 |
Percentage of participants requiring prescription of fluid restriction for the express purpose of treating hyponatremia during each period of the trial. Assessed descriptively at each visit.
| percentage of participants | Tolvaptan |
|---|---|
| Mild Hyponatremia (N=76) | 14.47 |
| Severe Hyponatremia (N=35) | 5.71 |
Percentage of participants requiring prescription of hypertonic saline for the express purpose of treating hyponatremia during each period of the trial, assessed descriptively at each visit.
| participants | Tolvaptan |
|---|---|
| Number of Participants Requiring Prescription of Hypertonic Saline | 2 |
Percentage of participants requiring prescription of other medicines for the express purpose of treating hyponatremia during each period of the trial, assessed descriptively at each visit.
| percentage of participants | Tolvaptan |
|---|---|
| Percentage of Participants Requiring Prescription of Other Medicines | 0 |
Body weight at each visit (assessed only for those with clinical evidence of hypervolemia at Baseline) and was summarized using descriptive statistics.
| kg | Tolvaptan |
|---|---|
| Day 31 (N= 26) | -0.5 ± 4.6 |
| Week 10 (N= 32) | -1.1 ± 3.7 |
| Week 18 (N= 27) | 0.2 ± 3.0 |
| Week 26 (N= 27) | 0.4 ± 5.4 |
| Week 34 (N= 26) | 0.5 ± 4.0 |
| Week 42 (N= 24) | 0.3 ± 4.6 |
| Week 50 (N= 22) | 1.0 ± 4.7 |
| Week 58 (N= 22) | 1.7 ± 4.5 |
| Week 70 (N= 18) | 1.7 ± 5.2 |
| Week 82 (N= 18) | 2.0 ± 7.0 |
| Week 94 (N= 18) | 3.0 ± 8.0 |
| Week 106 (N= 15) | 1.4 ± 8.0 |
| Week 118 (N= 13) | 2.2 ± 8.1 |
| Week 130 (N= 13) | 3.0 ± 9.0 |
| Week 142 (N= 12) | 3.8 ± 8.7 |
| Week 154 (N= 11) | 2.7 ± 7.9 |
| Week 166 (N= 9) | 2.9 ± 9.4 |
| Week 178 (N= 7) | 3.2 ± 8.6 |
| Week 190 (N= 5) | -2.4 ± 4.5 |
| Week 202 (N= 2) | -7.1 ± 0.4 |
| Week 214 (N= 2) | -8.5 ± 1.6 |
The PCS assess the physical and mental dimensions of health-related quality of life. The PCS is equal to the sum of the items of endurance activities, strength activities, gross coordination activities, and fine coordination activities. The PCS is a computed score with weighted function based on the 12 questions from the 8 subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health) of the SF-12v1 questionnaire per instructions by the scale's publisher. The scale ranges from 0 to 100 with 0 representing the lowest level of health and 100 indicating the highest level of health.
| Units on a scale | Tolvaptan |
|---|---|
| Day 14 (N= 102) | 1.0 ± 7.3 |
| Day 31 (N= 106) | 0.4 ± 7.9 |
| Week 10 (N= 106) | 0.3 ± 8.1 |
| Week 18 (N= 106) | 0.4 ± 8.1 |
| Week 26 (N= 106) | -0.9 ± 9.7 |
| Week 34 (N= 106) | -0.3 ± 9.4 |
| Week 42 (N= 106) | -1.1 ± 9.4 |
| Week 50 (N= 106) | -1.1 ± 9.0 |
| Week 58 (N= 106) | -0.9 ± 9.0 |
| Week 70 (N= 106) | -1.1 ± 9.1 |
| Week 82 (N= 106) | -0.9 ± 8.9 |
| Week 94 (N= 106) | -1.6 ± 9.1 |
| Week 106 (N= 106) | -1.7 ± 8.4 |
| Week 142 (N= 2) | -9.1 ± 10.8 |
| Week 166 (N= 2) | 4.6 ± 9.7 |
| Week 178 (N= 2) | -11.3 ± 2.5 |
| Week 190 (N= 6) | -2.2 ± 5.6 |
| Week 202 (N= 1) | 0.6 ± NA |
| Week 214 (N= 6) | 4.0 ± 9.2 |
The MCS assess the physical and mental dimensions of health-related quality of life. The MCS is equal to the sum of the items of concentration activities, calculating activities, language activities, and memory activities. The MCS is a computed score with weighted function based on the 12 questions from the 8 subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health) of the SF-12v1 questionnaire per instructions by the scale's publisher. The scale ranges from 0 to 100 with 0 representing the lowest level of health and 100 indicating the highest level of health.
| Units on a scale | Tolvaptan |
|---|---|
| Day 14 (N= 102) | -1.0 ± 8.8 |
| Day 31 (N= 106) | -1.0 ± 9.6 |
| Week 10 (N= 106) | -0.4 ± 9.8 |
| Week 18 (N= 106) | -2.0 ± 8.8 |
| Week 26 (N= 106) | -1.1 ± 8.8 |
| Week 34 (N= 106) | -2.7 ± 9.4 |
| Week 42 (N= 106) | -2.1 ± 10.1 |
| Week 50 (N= 106) | -1.9 ± 10.4 |
| Week 58 (N= 106) | -2.5 ± 11.4 |
| Week 70 (N= 106) | -2.6 ± 10.7 |
| Week 82 (N= 106) | -2.5 ± 10.5 |
| Week 94 (N= 106) | -2.6 ± 10.5 |
| Week 106 (N= 106) | -3.7 ± 11.6 |
| Week 142 (N= 2) | -11.2 ± 27.6 |
| Week 166 (N= 2) | 5.0 ± 13.6 |
| Week 178 (N= 2) | 0.4 ± 4.5 |
| Week 190 (N= 6) | -2.8 ± 8.2 |
| Week 202 (N= 1) | -0.8 ± NA |
| Week 214 (N= 6) | -0.5 ± 7.8 |
Analysis of individual items of Hyponatremia Disease-specific Survey was not conducted, because the analysis of Hyponatremia Disease-specific Survey was focused on the PCS and MCS summary scores since these 2 scores were developed. Subgroup analyses of Hyponatremia Disease-specific Survey were also not conducted.
No measurements were reported for this outcome.
Collected over AEs are reported from the signing of the informed consent until the follow-up visit (+7 days) after the last dose of study drug as scheduled or as an early termination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tolvaptan | — | 76/111 (68.5%) | 86/111 (77.5%) |
| Event | Tolvaptan |
|---|---|
| PneumoniaInfections and infestations | 10/111 |
| HyponatraemiaMetabolism and nutrition disorders | 10/111 |
| Cardiac failureCardiac disorders | 7/111 |
| Cardiac failure congestiveCardiac disorders | 7/111 |
| AscitesGastrointestinal disorders | 5/111 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 5/111 |
| Chest painGeneral disorders | 5/111 |
| EncephalopathyNervous system disorders | 5/111 |
| AnemiaBlood and lymphatic system disorders | 4/111 |
| Renal failureRenal and urinary disorders | 4/111 |
| Event | Tolvaptan |
|---|---|
| Oedema peripheralGeneral disorders | 25/111 |
| DiarrhoeaGastrointestinal disorders | 20/111 |
| NauseaGastrointestinal disorders | 18/111 |
| Urinary tract infectionInfections and infestations | 18/111 |
| HyponatraemiaMetabolism and nutrition disorders | 17/111 |
| AnaemiaBlood and lymphatic system disorders | 16/111 |
| FatigueGeneral disorders | 15/111 |
| HeadacheNervous system disorders | 15/111 |
| ThirstGeneral disorders | 14/111 |
| HypokalaemiaMetabolism and nutrition disorders | 13/111 |
| Age, Continuous(Years) | Tolvaptan |
|---|---|
| Mean | 64.6 ± 15.0 |
| Sex: Female, Male(Participants) | Tolvaptan |
|---|---|
| Female | 56 |
| Male | 55 |
No study locations are listed for this record.
The record gives a start of May 2004, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 6 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Otsuka Pharmaceutical Development & Commercialization, Inc. →